Welcome to our dedicated page for Liminatus Pharma news (Ticker: LIMN), a resource for investors and traders seeking the latest updates and insights on Liminatus Pharma stock.
Liminatus Pharma, Inc. develops cancer immunotherapies, with news centered on its IBA101 program, a next-generation CD47-blocking monoclonal antibody for immuno-oncology. Company updates describe CD47 blockade, innate immune surveillance, macrophage-mediated tumor clearance, and clinical-development planning for use with established PD-1/PD-L1 checkpoint inhibitor approaches.
Recurring LIMN news also covers financing and capital-structure actions, shareholder voting and governance matters, Nasdaq-related disclosures, and regulatory communications tied to the company's public-company status and oncology development strategy.
Liminatus Pharma (Nasdaq: LIMN) received a Nasdaq delisting notice after not regaining compliance with market value requirements. Nasdaq cited the $50,000,000 market value of listed securities and $15,000,000 market value of publicly held shares rules.
Unless Liminatus appeals by May 27, 2026, trading could be suspended May 29, 2026. The company plans to request a hearing, which would stay any suspension or delisting action pending the Panel decision.
Liminatus Pharma (LIMN) signed a definitive Merger Agreement to acquire InnocsAI via a subsidiary, aiming to expand its oncology cell therapy pipeline.
InnocsAI members will receive 1.6 billion Liminatus shares at $0.20 (about $320 million) plus contingent value rights to 20% of future net proceeds from certain strategic deals involving the acquired assets. The transaction adds CAR-T and antibody-based programs, including IBC101, a CD19xCD22 bivalent CAR-T authorized in Korea for a Phase 1/2a DLBCL study; INC101, a preclinical dual-antigen MSLNxCD276 CAR-T for solid tumors with a related armoured construct INC102; and a CS1 antibody platform intended to enable future trivalent CD19xCD22xCS1 CAR-T candidates. Closing is subject to shareholder and regulatory approvals and other customary conditions.
Liminatus (NASDAQ:LIMN) announced planned initiation of a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immunity and complement PD-1/PD-L1 therapies.
The seamless study will begin with monotherapy dose escalation then add combination cohorts, initially focusing on lung cancer, and will include translational analyses to characterize immune activity. The company targets readiness after completing manufacturing, nonclinical, and regulatory preparations.
Liminatus Pharma (NASDAQ: LIMN) priced a best-efforts public offering of 13,813,000 common shares (or pre-funded warrants) and warrants to purchase 20,719,500 shares at a combined public offering price of $0.29 per share on February 17, 2026.
Gross proceeds are expected to be approximately $4.0 million, with potential additional proceeds of about $6.0 million if warrants are fully exercised; closing expected on or about February 18, 2026.
Liminatus Pharma (NASDAQ: LIMN) signed a Memorandum of Understanding with Capital Trust Group for a USD 30,000,000 equity financing via an earn-out mechanism to support R&D of its immuno-oncology programs. The investment is subject to due diligence, negotiation of definitive agreements, Nasdaq and U.S. securities compliance, and effectiveness of a registration statement for resale of the shares. Both parties target execution of definitive agreements in November 2025 and plan to discuss further strategic cooperation beginning mid-November, including potential digital bond financing programs.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, announced plans to establish "American BNB Strategy," a subsidiary focused on cryptocurrency investments. The company aims to raise and deploy up to $500 million for strategic, long-term investments in BNB coin, the native token of the Binance ecosystem.
While maintaining its core focus on cancer therapeutics and diagnostics, Liminatus views this expansion into digital assets as crucial for long-term growth. The company plans to utilize Ceffu's custody infrastructure for institutional-grade security and is currently working with Digital Offering on the capital raise process, pending regulatory clearance and market conditions.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, has initiated a strategic review to explore forming a digital asset investment subsidiary. The company is evaluating options to target up to $500 million in capital formation through various financing tools.
The proposed subsidiary would focus on digital asset allocation and blockchain-integrated financial structures, operating independently from Liminatus's core clinical pipeline. Currently, no capital has been raised or committed, no agreements executed, and no partnerships established. The initiative remains subject to Board approval, regulatory compliance, and market conditions.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has engaged Digital Offering LLC as its exclusive placement agent to evaluate potential strategic capital raising options.
The engagement supports Liminatus's exploration of a digital asset treasury strategy and may include various financing structures such as convertible debentures, equity-linked securities, or alternative instruments. Digital Offering will help source institutional and digital asset-focused investors while ensuring regulatory compliance.
CEO Chris Kim emphasized that while no financing transaction has been finalized, this partnership allows the company to explore both traditional and digital asset funding opportunities strategically.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced the initiation of a strategic review to evaluate potential blockchain and digital asset integration into its treasury management strategy.
While maintaining its primary focus on cancer therapy development, the company is exploring regulated digital asset opportunities to optimize its balance sheet and enhance treasury efficiency for non-operating capital reserves. CEO Chris Kim emphasized that this exploratory process does not represent a shift in business focus and any future implementation would require Board approval and SEC compliance.